Alkermes plc (ALKS): יחס שווי שוק לרווח וקצב צמיחה

Alkermes plc operates in the stable biopharmaceutical sector of the US and EU, protected by international law. The PEG ratio history demonstrates the current market value, where 0.00 is the current level of the indicator. Revenues are based on the sale of patented treatments for schizophrenia and addictions. High potential is driven by complex clinical trials and unique drug delivery systems.

The specific nature of Alkermes plc (ALKS), characterized by a moderate reliance on external CRO partners for clinical trials, makes profit dynamics sensitive to outsourcing efficiency. By analyzing the PEG ratio, an investor compares the stock's market value with its earnings growth rate, where a value below one signals that the asset is undervalued relative to its expansion, helping to avoid freezing capital in overvalued securities.